Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1960 1
1973 1
1977 2
1978 1
1979 7
1980 6
1981 3
1982 1
1983 2
1985 1
1986 5
1987 2
1988 2
1989 3
1991 1
1992 1
1993 2
1994 1
1995 1
1996 2
1998 2
1999 3
2000 3
2001 7
2002 8
2003 7
2004 13
2005 21
2006 16
2007 19
2008 19
2009 26
2010 35
2011 30
2012 49
2013 49
2014 52
2015 55
2016 64
2017 51
2018 53
2019 62
2020 76
2021 69
2022 73
2023 84
2024 121
2025 102
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,117 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. Among authors: li jr. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception.
Zhu B, Chen P, Aminu M, Li JR, Fujimoto J, Tian Y, Hong L, Chen H, Hu X, Li C, Vokes N, Moreira AL, Gibbons DL, Solis Soto LM, Parra Cuentas ER, Shi O, Diao S, Ye J, Rojas FR, Vilar E, Maitra A, Chen K, Navin N, Nilsson M, Huang B, Heeke S, Zhang J, Haymaker CL, Velcheti V, Sterman DH, Kochat V, Padron WI, Alexandrov LB, Wei Z, Le X, Wang L, Fukuoka J, Lee JJ, Wistuba II, Pass HI, Davis M, Hanash S, Cheng C, Dubinett S, Spira A, Rai K, Lippman SM, Futreal PA, Heymach JV, Reuben A, Wu J, Zhang J. Zhu B, et al. Among authors: li jr. Cancer Cell. 2025 Jun 9;43(6):1125-1140.e10. doi: 10.1016/j.ccell.2025.04.003. Epub 2025 May 8. Cancer Cell. 2025. PMID: 40345189 Free article.
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial.
Powles TB, Van der Heijden MS, Loriot Y, Bedke J, Valderrama BP, Iyer G, Kikuchi E, Hoffman-Censits J, Vulsteke C, Drakaki A, Rausch S, Arafat W, Park SH, Swami U, Li JR, Duran I, Gorla S, Homet Moreno B, Yu X, Lu YT, Gupta S. Powles TB, et al. Among authors: li jr. Ann Oncol. 2025 Oct;36(10):1212-1219. doi: 10.1016/j.annonc.2025.05.536. Epub 2025 Jun 1. Ann Oncol. 2025. PMID: 40460988 Free article. Clinical Trial.
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).
Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY, Sun JH, Jin ZC, Chen JJ, Ge NJ, Ding WB, Li WH, Huang JH, Mu W, Gu SZ, Li JP, Zhao H, Wen SW, Lei YM, Song YS, Yuan CW, Wang WD, Huang M, Zhao W, Wu JB, Wang S, Zhu X, Han JJ, Ren WX, Lu ZM, Xing WG, Fan Y, Lin HL, Zhang ZS, Xu GH, Hu WH, Tu Q, Su HY, Zheng CS, Chen Y, Zhao XY, Fang ZT, Wang Q, Zhao JW, Xu AB, Xu J, Wu QH, Niu HZ, Wang J, Dai F, Feng DP, Li QD, Shi RS, Li JR, Yang G, Shi HB, Ji JS, Liu YE, Cai Z, Yang P, Zhao Y, Zhu XL, Lu LG, Teng GJ; CHANCE001 Investigators. Zhu HD, et al. Among authors: li jr. Signal Transduct Target Ther. 2023 Feb 8;8(1):58. doi: 10.1038/s41392-022-01235-0. Signal Transduct Target Ther. 2023. PMID: 36750721 Free PMC article.
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E, Garcia-Del-Muro X, De Giorgi U, Mencinger M, Izumi K, Panni S, Gumus M, Özgüroğlu M, Kalebasty AR, Park SH, Alekseev B, Schutz FA, Li JR, Ye D, Vogelzang NJ, Bernhard S, Tayama D, Mariathasan S, Mecke A, Thåström A, Grande E; IMvigor130 Study Group. Galsky MD, et al. Among authors: li jr. Lancet. 2020 May 16;395(10236):1547-1557. doi: 10.1016/S0140-6736(20)30230-0. Lancet. 2020. PMID: 32416780 Clinical Trial.
Metal-Organic Frameworks for Food Safety.
Wang PL, Xie LH, Joseph EA, Li JR, Su XO, Zhou HC. Wang PL, et al. Among authors: li jr. Chem Rev. 2019 Sep 25;119(18):10638-10690. doi: 10.1021/acs.chemrev.9b00257. Epub 2019 Jul 30. Chem Rev. 2019. PMID: 31361477 Review.
Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells.
Brunet L, Alexandre D, Lee J, Blanquer-Rosselló MDM, Bracquemond D, Guernet A, Chhouri H, Goupil M, Kherrouche Z, Arabo A, Mancini M, Cartier D, Yao S, Godefroy D, Dehedin J, Li JR, Duparc C, Jamme P, Vinchent A, Bérard C, Tulasne D, Arena S, Bardelli A, Cheng C, Cho BC, Wurtz O, Coulouarn C, Maraver A, Aaronson SA, Cortot AB, Anouar Y, Grumolato L. Brunet L, et al. Among authors: li jr. Nat Commun. 2025 Aug 22;16(1):7853. doi: 10.1038/s41467-025-61788-w. Nat Commun. 2025. PMID: 40846697 Free PMC article.
1,117 results